1. Home
  2. LU vs CRVS Comparison

LU vs CRVS Comparison

Compare LU & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lufax Holding Ltd each representing two (2)

LU

Lufax Holding Ltd each representing two (2)

SELL

Current Price

$7.17

Market Cap

715.9M

Sector

Finance

ML Signal

SELL

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

SELL

Current Price

$10.78

Market Cap

843.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LU
CRVS
Founded
2005
2014
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
715.9M
843.7M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
LU
CRVS
Price
$7.17
$10.78
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$23.54
★ $31.50
AVG Volume (30 Days)
555.1K
★ 893.7K
Earning Date
10-27-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 48.04
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.80
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$6.39
52 Week High
$9.60
$26.95

Technical Indicators

Market Signals
Indicator
LU
CRVS
Relative Strength Index (RSI) 61.15 49.55
Support Level $1.38 $9.40
Resistance Level $9.31 $10.81
Average True Range (ATR) 0.61 0.67
MACD -0.30 0.13
Stochastic Oscillator 25.31 49.55

Price Performance

Historical Comparison
LU
CRVS

About LU Lufax Holding Ltd each representing two (2)

Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: